Jie Ling - Concepedia

Author

Jie Ling

Brigham and Women's Hospital ORCID

Also Known As

J LING, J Ling, Jie Ling, Jingwen Ling

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Brigham and Women's Hospital La Roche College

About

Jie Ling is an author at Brigham and Women's Hospital specializing in medicine, pharmacotherapy, and clinical chemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	624
2	Clinical Nutrition	2	2	440
3	Health Sciences	1	1	261
4	Cell Biology	1	1	17
5	Emergency Medicine	1	1	179

Jie Ling

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Nutritional assessment with bioelectrical impedance analysis in maintenance hemodialysis patients. Glenn M. Chertow, Edmund G. Lowrie, Douglas W. Wilmore, Journal of the American Society of Nephrology NutritionDeuterium OxideDialysis TherapyBody CompositionElectrolyte Disturbance	1995	261
METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS Jie Ling, Kim A. Johnson, Zhuang Miao, Drug Metabolism and Disposition	2005	219
The Association of Intradialytic Parenteral Nutrition Administration with Survival in Hemodialysis Patients Glenn M. Chertow, Jie Ling, Nancy L. Lew, American Journal of Kidney Diseases NutritionHemodialysisHemodialysis PatientsMedicineKidney Failure	1994	179
Predicting Hemodialysis Access Failure with Color Flow Doppler Ultrasound William H. Bay, Mitchell L. Henry, J. Michael Lazarus, American Journal of Nephrology	1998	137
Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects Paul Frohna, Jianfeng Lu, Steve Eppler, The Journal of Clinical Pharmacology Oral BioavailabilityHealthy SubjectsPharmacological StudyMedicineReceptor Tyrosine Kinase	2006	109
Population Pharmacokinetics of Golimumab, an Anti‐Tumor Necrosis Factor‐α Human Monoclonal Antibody, in Patients With Psoriatic Arthritis Zhenhua Xu, Thuy Vu, Howard Lee, The Journal of Clinical Pharmacology	2009	90
Lack of Racial Differences in the Pharmacokinetics of Subcutaneous Golimumab in Healthy Japanese and Caucasian Male Subjects Jie Ling, Sally Lyn, Zhenhua Xu, The Journal of Clinical Pharmacology Drug SafetyTranslational MedicineSubcutaneous GolimumabCaucasian Male SubjectsPharmacology	2010	32
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma Steven O’Day, Anna C. Pavlick, Mark R. Albertini, Investigational New Drugs Cnto 95Dose LevelsMedicineMelanomaImmune Checkpoint Inhibitor	2011	26
Effect of lithium in immunodeficiency: improved blood cell formation in mice with decreased hematopoiesis as the result of LP-BM5 MuLV infection Gallicchio Vs, K TSE, Jie Ling, Antiviral Research Blood Cell FormationHematologyImmunologyBlood CellAntiviral Response	1995	17
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer Hilary Calvert, Chris Twelves, Malcolm Ranson, Anti-Cancer Drugs	2014	15

Page 1